Scarica l'app Stockscreener
35.09
0.23%
0.08
Precedente Chiudi:
$35.01
Aprire:
$35.96
Volume 24 ore:
1.50M
Relative Volume:
1.29
Capitalizzazione di mercato:
$2.52B
Reddito:
-
Utile/perdita netta:
$-368.95M
Rapporto P/E:
-6.3279
EPS:
-5.5453
Flusso di cassa netto:
$-293.81M
1 W Prestazione:
+4.28%
1M Prestazione:
+2.15%
6M Prestazione:
-26.42%
1 anno Prestazione:
+67.73%
Intervallo 1D:
$34.58
$36.67
Intervallo di 1 settimana:
$32.95
$36.67
Portata 52W:
$19.07
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
35.09 | 2.52B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics Inc (VERA) Institutional Confidence - TradingKey
(VERA) Risk Channels and Responsive Allocation - Stock Traders Daily
Vera Therapeutics Inc (VERA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vera Therapeutics Inc (VERA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vera Therapeutics Inc (VERA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vera Therapeutics Inc (VERA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vera Therapeutics stock gains 4.13% as Official VeraTx promotes new IgANime accessory features - Traders Union
Vera Therapeutics Inc (VERA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vera Therapeutics Inc (VERA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vera Therapeutics Inc (VERA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vera Therapeutics (VERA) Appears Attractive After Latest FDA Agreement - Yahoo Finance
Insiders At Vera Therapeutics Sold US$1.9m In Stock, Alluding To Potential Weakness - Moomoo
Vera Therapeutics Inc (VERA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vera Therapeutics (VERA) Receives a Buy from Wells Fargo - The Globe and Mail
Vera Therapeutics moves closer to full approval for kidney disease drug after FDA alignment - MSN
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative - Yahoo Finance
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis - Yahoo Finance
(VERA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
Vera Therapeutics grants inducement awards to 10 new employees - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Grants Inducement Stock Awards to New Employees - Quiver Quantitative
Vera Therapeutics gives new hires 28,800 stock option shares - Stock Titan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Goldman Sachs Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Jefferies reiterates Vera Therapeutics stock rating on FDA alignment By Investing.com - Investing.com Canada
Vera Therapeutics stock gets Outperform rating from William Blair By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review - Investing.com UK
Why is Vera Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Vera Therapeutics Advances Atacicept for IgA Nephropathy with FDA Agreement - Intellectia AI
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path - Investing.com
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path By Investing.com - Investing.com Canada
Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops - Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment - Yahoo Finance
Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval - marketscreener.com
Goldman Sachs reiterates Vera Therapeutics stock rating on FDA timeline By Investing.com - Investing.com Canada
Vera Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
Why is Vera Therapeutics stock sliding today? - Investing.com
Raymond James reiterates Strong Buy on Vera Therapeutics stock By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review By Investing.com - Investing.com Australia
Vera Therapeutics stock rating reiterated at Buy by TD Cowen on FDA alignment - Investing.com Canada
Vera Therapeut aligns with FDA on earlier ORIGIN 3 eGFR analysis; eGFR readout in Q3 2026 - TradingView
Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA) - Stock Titan
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ... - Caledonian Record
Vera Therapeutics Announces Alignment with U.S. FDA on - GlobeNewswire
VERA News | VERA THERAPEUTICS INC (NASDAQ:VERA) - ChartMill
Vera Therapeutics, Inc. Files Form 8-K Detailing Company Information and SEC Compliance (May 21, 2026) - Minichart
Liquidity Mapping Around (VERA) Price Events - Stock Traders Daily
Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending (NASDAQ:VERA) - Seeking Alpha
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):